Loading…
← CockpitCompetitor Analysis › RIGL Rigel Pharmaceuticals, Inc.Open in the cockpit ↗

Rigel Pharmaceuticals, Inc.RIGLCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum strong 77
Mkt cap
$801M
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$11.6M
20-day average traded
Fwd P/E
10.8×
forward earnings
ROIC−WACC
+5.5 pp
WACC 11.4%
Hurdle
-21 pp
Req g minus delivered
Next earnings
111 days
9 Mar 2027
Close · USD$42.53
1D-0.9%
1W-4.5%
1M-11.6%
3M-6.0%
6M+47.6%
YTD-0.7%
1Y+0.1%
ATR %5.7%
Beta1.02
52w lowhigh19.1% off high

What Rigel Pharmaceuticals does

Employees: 174

Rigel Pharmaceuticals at a glance

Size Rigel Pharmaceuticals (RIGL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $801M, the 2367th largest of 3,085 United States companies the cockpit tracks. Shares closed at $42.53 on 18 Nov 2026.

Performance Over six months the shares gained 47.6%, against -8.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +2.7%); the operating margin is 26.3% (peer median 5.0%).

Valuation It trades at 10.8× forward earnings against a peer median of 19.6× (4th cheapest of 8).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.5 points above its cost of capital (11.4% WACC).

Short interest Short interest is 13.5% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026RIGL 146Peer median 92
Six months, rebased to 100: Rigel Pharmaceuticals against the median of its 20 peers (local-currency closes).

Rigel Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$288M$294M$179M$117M$120M
Revenue growth—+64%+53%-3%—
Gross profit$258M$275M$161M$110M$118M
EBITDA$79.6M$128M$26.4M-$19.3M-$53.2M
Net income$307M$367M$17.5M-$25.1M-$58.6M
Free cash flow$89.9M$75.7M$31.4M-$5.74M-$74.2M
Capital expenditure$70.6M$0$396,000$15.0M$450,000
Total debt$7.79M$53.3M$60.0M$60.6M$41.6M

Quarterly statements and history in the cockpit →

Rigel Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%688073SUVENSANOFICOLLORICGUDIRWD6078002349ARDX000411002082603229BLISSGVS300267RIGL6-month return →1-month return →
Up and to the right = strong over both horizons. Rigel Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×688073SANOFICOLLGUDIRWD6078ARDXRIGLRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Rigel Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-25%0%25%688073SANOFICOLLGUD002349002082BLISSGVS002390RIGLGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Rigel Pharmaceuticals is the large dot.

Rigel Pharmaceuticals competitors and peer comparison

How Rigel Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rigel Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureRIGLPeer medianRank in peer set
1-month return-11.6%-2.9%6th lowest of 19
6-month return+47.6%-8.3%2nd highest of 19
Distance from 52-week high-19.1%-34.8%4th highest of 19
Revenue growth (TTM)+2.2%+2.7%10th highest of 19
Operating margin26.3%5.0%3rd highest of 19
Forward P/E10.8×19.6×4th cheapest of 8
Growth the price implies (Req g, 7 yrs)1.5%6.6%4th least demanding of 10
Growth delivered (Del g)+22.1%+10.1%3rd highest of 10
Hurdle (Req g minus delivered)-20.6 pp-5.1 pp2nd least demanding of 10
ROIC minus cost of capital+5.5 pp-2.3 pp4th highest of 18
EV / EBITDA8.9×9.7×4th cheapest of 7
Net debt / EBITDA-1.1×0.3×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a

Questions

Which companies are Rigel Pharmaceuticals's closest peers?
The cockpit's peer set: Bide Pharmatech (688073.SS), Suven Life Sciences (SUVEN.NS), Sanofi India (SANOFI.NS), Collegium Pharmaceutical (COLL), Oric Pharmaceuticals (ORIC), Knight Therapeutics (GUD.TO), Ironwood Pharmaceuticals (IRWD), Bambusa Therapeutics (BBTX).
Is Rigel Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 10.8× against a peer median of 19.6×, 4th cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has Rigel Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +47.6% against -8.3% for the median peer; over one year +0.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.